1. Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response.
- Author
-
Ogbue, Olisaemeka D., Bahaj, Waled, Kewan, Tariq, Ahmed, Ramsha, Dima, Danai, Willimas, Nakisha, Durmaz, Arda, Visconte, Valeria, Maskal, Sara M., Gurnari, Carmelo, Steven, Rosenblatt, and Maciejewski, Jaroslaw P.
- Subjects
SPLENECTOMY ,IDIOPATHIC thrombocytopenic purpura ,AUTOIMMUNE hemolytic anemia ,TREATMENT effectiveness ,TREATMENT failure ,CYTOPENIA - Abstract
Background: Splenectomy is commonly used to treat refractory immune–mediated cytopenia, but there are no established factors that are associated with response to the procedure. Objectives: A cohort study was conducted to evaluate the hematologic and surgical outcomes of splenectomy in adult patients with immune cytopenias and identify preoperative factors associated with response. Methods: Data from the Cleveland Clinic Foundation for 1824 patients aged over 18 who underwent splenectomy from 2002 to 2020 were analyzed. Results: The study found that the most common indications for splenectomy were immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia, with a median age of 55 years and median time from diagnosis to splenectomy of 11 months. Hematologic response rates were 74% overall, with relapse in 12% of cases. Postsplenectomy discordant diagnoses were present in 13% of patients, associated with higher relapse rates. Surgery‐related complications occurred in 12% of cases, whereas only 3% of patients died from disease complications. On univariate analysis, preoperative factors associated with splenectomy treatment failure were ≥3 lines of pharmacologic treatment, whereas isolated thrombocytopenia, primary ITP, and age ≤40 years had a strong association with response. The multivariable regression confirmed that treatment failure with multiple lines of medical therapy was associated with the failure to respond to splenectomy. Conclusion: Overall, the study demonstrates that splenectomy is an effective treatment option for immune‐mediated cytopenias with a low complication rate. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF